# BAL/BOT/agenT-797 in pMMR CRC With Liver Metastases

> **NCT07550088** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Darren Sigal, MD** · enrollment: 17 (estimated)

## Conditions studied

- Colorectal Cancer Metastatic

## Interventions

- **DRUG:** Balstilimab (BAL)
- **DRUG:** Botensilimab (BOT)
- **DRUG:** agenT-797

## Key facts

- **NCT ID:** NCT07550088
- **Lead sponsor:** Darren Sigal, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2028-09
- **Final completion:** 2028-12
- **Target enrollment:** 17 (ESTIMATED)
- **Last updated:** 2026-04-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07550088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07550088, "BAL/BOT/agenT-797 in pMMR CRC With Liver Metastases". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07550088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*